Literature DB >> 4290022

The effects of secretin, pancreozymin, and gastrin on insulin and glucagon secretion in anesthetized dogs.

R H Unger, H Ketterer, J Dupré, A M Eisentraut.   

Abstract

The effects upon islet hormone secretion of highly purified preparations of secretin and of pancreozymin-cholecystokinin and of a crude gastrin-containing extract of hog antrum have been studied in acutely operated dogs. All three preparations were shown to cause a striking increase in insulin concentration in the pancreaticoduodenal venous plasma after their rapid endoportal injection in anesthetized dogs. With each hormone preparation, the peak in insulin secretion occurred 1 minute after injection, and a rapid decline was observed immediately thereafter. Whereas secretin and gastrin failed to alter significantly the pancreaticoduodenal venous glucagon or arterial glucose concentration, pancreozymin caused a dramatic rise in pancreaticoduodenal venous glucagon concentration, which reached a peak 3 minutes after injection, and hyperglycemia was noted to occur soon thereafter. Endoportal infusion of secretin and pancreozymin for 20 minutes caused responses that were sustained but qualitatively identical to the responses noted after rapid injection of the hormones. The beta-cytotropic effect of secretin was abolished by the infusion of epinephrine. These results could not be attributed to the small degree of contamination of the enteric hormone preparations with insulin or glucagon, and it would appear that secretin, pancreozymin, and probably gastrin have insulin-releasing activity and that pancreozymin has, in addition, glucagon-releasing activity.The demonstration that these three hormones possess insulin-releasing activity suggests that there is in the gastrointestinal tract a chain of betacytotropic hormones from antrum to ileum that is capable of augmenting insulin secretion as required for disposal of substrate loads. It is suggested that the existence of this "entero-insular axis" prevents high substrate concentrations that would otherwise follow ingestion of large meals were the insular response entirely a function of arterial substrate concentration.

Entities:  

Mesh:

Substances:

Year:  1967        PMID: 4290022      PMCID: PMC442047          DOI: 10.1172/JCI105565

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  18 in total

1.  USE OF LIVER ADENYL CYCLASE FOR ASSAY OF GLUCAGON IN HUMAN GASTRO-INTESTINAL TRACT AND PANCREAS.

Authors:  M H MAKMAN; E W SUTHERLAND
Journal:  Endocrinology       Date:  1964-07       Impact factor: 4.736

2.  THE CONSTITUTION AND PROPERTIES OF TWO GASTRINS EXTRACTED FROM HOG ANTRAL MUCOSA.

Authors:  R A GREGORY; H J TRACY
Journal:  Gut       Date:  1964-04       Impact factor: 23.059

3.  AN INTESTINAL HORMONE AFFECTING GLUCOSE DISPOSAL IN MAN.

Authors:  J DUPRE
Journal:  Lancet       Date:  1964-09-26       Impact factor: 79.321

4.  Immunoassay of endogenous plasma insulin in man.

Authors:  R S YALOW; S A BERSON
Journal:  J Clin Invest       Date:  1960-07       Impact factor: 14.808

5.  Glucagon antibodies and an immunoassay for glucagon.

Authors:  R H UNGER; A M EISENTRAUT; M S McCALL; L L MADISON
Journal:  J Clin Invest       Date:  1961-07       Impact factor: 14.808

6.  Effects of secretin on insulin and glucagon in portal and peripheral blood in man.

Authors:  J Dupré; L Rojas; J J White; R H Unger; J C Beck
Journal:  Lancet       Date:  1966-07-02       Impact factor: 79.321

7.  Immunochemical glucagon in human pancreas, gut, and plasma.

Authors:  E Samols; J Tyler; C Megyesi; V Marks
Journal:  Lancet       Date:  1966-10-01       Impact factor: 79.321

8.  Effect of secretin on insulin secretion.

Authors:  R H Unger; H Ketterer; A Eisentraut; J Dupré
Journal:  Lancet       Date:  1966-07-02       Impact factor: 79.321

9.  Effect of glucagon on serum insulin, plasma glucose and free fatty acids in man.

Authors:  P M Crockford; D Porte; F C Wood; R H Williams
Journal:  Metabolism       Date:  1966-02       Impact factor: 8.694

10.  Stimulation of release of insulin by an extract of intestinal mucosa.

Authors:  J Dupré; J C Beck
Journal:  Diabetes       Date:  1966-08       Impact factor: 9.461

View more
  75 in total

1.  [Glucose tolerance and insulin secretion in oral and intravenous glucose load after intraabdominal operation (author's transl)].

Authors:  R Bittner; H G Beger; R Roscher; E Kraas
Journal:  Langenbecks Arch Chir       Date:  1975

2.  Relationship between changes of serum cholecystokinin-pancreozymin and serum insulin after different stimuli.

Authors:  J A Grayburn; R F Harvey; R D Jennings; L Dowsett; M Hartog
Journal:  Diabetologia       Date:  1975-02       Impact factor: 10.122

Review 3.  Secretin: Should we revisit its metabolic outcomes?

Authors:  D H St-Pierre; F Broglio
Journal:  J Endocrinol Invest       Date:  2010-05-05       Impact factor: 4.256

4.  The effects of gastrin, gastric inhibitory polypeptide, secretin, and the octapeptide of cholecystokinin upon immunoreactive somatostatin release by the perfused canine pancreas.

Authors:  E Ipp; R E Dobbs; V Harris; A Arimura; W Vale; R H Unger
Journal:  J Clin Invest       Date:  1977-11       Impact factor: 14.808

5.  Insulin release from mouse islets. Effect of glucose and hormones on adenylate cyclase.

Authors:  B Davis; N R Lazarus
Journal:  Biochem J       Date:  1972-09       Impact factor: 3.857

6.  Specific biologic effects of intestinal glucagon-like materials.

Authors:  R A Gutman; G Fink; N Voyles; H Selawry; J C Penhos; A Lepp; L Recant
Journal:  J Clin Invest       Date:  1973-05       Impact factor: 14.808

7.  [Levels of pancreatic hydrolases in pancreas and small bowel of two types of obese mice with hyperinsulinism: the obese-hyperglycemic Bar-Harbor mouse (OH) and the New-Zealand mouse (NZO)].

Authors:  M H Khayat; J Rathé; A Vandermeers; J Christophe
Journal:  Diabetologia       Date:  1968-08       Impact factor: 10.122

8.  Oral glucose augmentation of insulin secretion. Interactions of gastric inhibitory polypeptide with ambient glucose and insulin levels.

Authors:  D K Andersen; D Elahi; J C Brown; J D Tobin; R Andres
Journal:  J Clin Invest       Date:  1978-07       Impact factor: 14.808

9.  Discrepancies between the doses of cholecystokinin or caerulein-stimulating exocrine and endocrine responses in perfused isolated rat pancreas.

Authors:  M Otsuki; C Sakamoto; H Yuu; M Maeda; S Morita; A Ohki; N Kobayashi; K Terashi; K Okano; S Baba
Journal:  J Clin Invest       Date:  1979-03       Impact factor: 14.808

10.  [Persisting hyperlipidemias as risk factors of diabetic macroangiopathy].

Authors:  K H Vogelberg; G Meurers
Journal:  Klin Wochenschr       Date:  1986-06-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.